Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-04-30T18:31:01.558Z Has data issue: false hasContentIssue false

Chapter 23 - Botulinum neurotoxin A treatment for ischemic digits

Published online by Cambridge University Press:  05 February 2014

Michael W. Neumeister
Affiliation:
Department of Plastic Surgery, Southern Illinois University School of Medicine, Carbondale, IL, USA
Kelli Webb
Affiliation:
Department of Plastic Surgery, Southern Illinois University School of Medicine, Carbondale, IL, USA
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Raynaud’s phenomenon

Raynaud’s phenomenon is a vasospastic disorder that affects over 9 million people in the USA (National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2006). Maurice Reynaud’s description of arterial insufficiency to the fingers in 1862 led to his name being the eponym of this condition. He described the process as a “local asphyxia of the extremities” as a result of “increased irritability of the central parts of the cord presiding over vascular innervation.” Raynaud’s phenomenon is nine times more common in females and typically occurs between the ages of 15–40 years. These patients have an exaggerated vasoconstriction of their digital arteries in response to certain environmental triggers, which leads to pale, cold, numb and sometimes painful digits. These symptoms can last minutes to hours and may reoccur several times through the day. For the majority of patients, the symptoms are simply bothersome, but for 20% the symptoms are so severe that they seek medical attention. The digital artery vasospasm leads to diminished blood supply to the fingertips, which causes pain, ulcerations and disuse. Many patients require digit amputations for recalcitrant ulcers or exposure of the distal phalanx. The resultant digit ischemia may be also associated with considerable morbidity associated with loss of function, disability and depression.

Primary Raynaud’s disease is an idiopathic condition, and secondary Raynaud’s disease is associated with other connective tissue disorders. Secondary Raynaud’s disease affects 90% of patients with scleroderma, 90% of patients with mixed connective tissue disease, 33% of patients with lupus and 33% of people with Sjögren’s syndrome. The pathophysiology of primary versus secondary Raynaud’s disease is likely different, with secondary Raynaud’s disease invariably causing more severe and debilitating symptoms (Figs. 23.1 and 23.2).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

de Trafford, JC, Lafferty, K, Potter, CE, Roberts, VC, Cotton, LT (1988). An epidemiological survey of Raynaud’s phenomenon. Eur J Vasc Surg, 2, 167–70.CrossRefGoogle ScholarPubMed
Fregene, A, Ditmars, D, Siddiqui, A (2009). Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg Am, 34, 446–52.CrossRefGoogle ScholarPubMed
National Institute of Arthritis and Musculoskeletal and Skin Diseases (2006). Questions and Answers about Raynaud’s Phenomenon (NIH Publication No. 06–4911). Bethesda, MD: National Institutes of Health.Google Scholar
Neumeister, MW (2010). Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg, 35, 2085–92.CrossRefGoogle ScholarPubMed
Neumeister, MW, Chambers, CB, Herron, MS et al. (2009). Botox therapy for ischemic digits. Plast Reconstr Surg, 124, 191–201.CrossRefGoogle ScholarPubMed
Sycha, T, Graninger, M, Auff, E, Schnider, P (2004). Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest, 34, 312–13.CrossRefGoogle ScholarPubMed
Van Beek, AL, Lim, PK, Gear, AJL, Pritzker, MR (2007).Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg, 119, 217.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×